REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Core Insights - REGENXBIO is advancing its late-stage gene therapy pipeline for rare and retinal diseases, with multiple catalysts expected in 2026 [1] - The company reported financial results for Q4 and the full year 2025, highlighting significant revenue growth and ongoing operational developments [2] Financial Results - Cash, cash equivalents, and marketable securities totaled $240.9 million as of December 31, 2025, down from $244.9 million a year earlier, primarily due to operating expenses [2] - Revenues for Q4 2025 were $30.3 million, up from $21.2 million in Q4 2024, while full-year revenues reached $170.4 million compared to $83.3 million in 2024 [2] - Research and development expenses increased to $59.6 million for Q4 2025 and $228.3 million for the full year, driven by clinical trial costs related to RGX-202 [2] - General and administrative expenses rose to $22.4 million for Q4 2025 and $82.9 million for the full year, attributed to professional services and consulting [2] - The net loss for Q4 2025 was $67.1 million, or $1.30 per share, compared to a net loss of $51.2 million, or $1.01 per share, in Q4 2024 [2] Program Highlights - RGX-202 is a gene therapy for Duchenne muscular dystrophy, with pivotal trial enrollment completed and topline data expected in early Q2 2026 [1] - Surabgene lomparvovec (sura-vec) is being developed for wet age-related macular degeneration and diabetic retinopathy, with global regulatory submissions anticipated in 2027 [1] - The company plans to initiate a Phase III expansion for sura-vec following an interim analysis of the NAAVIGATE study, with a $100 million milestone payment from AbbVie expected upon first patient dosing [1] Operational Developments - REGENXBIO is focused on executing its mission to deliver new medicines through gene therapy, leveraging in-house manufacturing capabilities and global partnerships [1] - The company is preparing for a pre-BLA meeting with the FDA in mid-2026 to align on the BLA submission for RGX-202 [1] - Positive functional data from the Phase I/II trial of RGX-202 showed significant improvement in patients compared to expected disease progression [1]